Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 12:9:506.
doi: 10.3389/fonc.2019.00506. eCollection 2019.

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development

Juan Huang  1 , Jialong Yu  2 , Lin Tu  2 , Nanqu Huang  2 , Hang Li  2 , Yong Luo  2
Affiliations
Review

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development

Juan Huang et al. Front Oncol. .

Abstract

Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target. First, IDH mutations can produce high levels of 2-hydroxyglutaric acid (2-HG), thereby inhibiting glioma stem cell differentiation. At the same time, IDH mutations can upregulate vascular endothelial growth factor (VEGF) to promote the formation of the tumor microenvironment. In addition, IDH mutations can also induce high levels of hypoxia-inducible factor-1α (HIF-1α) to promote glioma invasion. Ultimately, these changes will lead to the development of glioma. Currently, a large number of IDH inhibitors and vaccines have entered clinical trials, representing progress in the treatment of glioma patients.

Keywords: 2-hydroxyglutaric acid; IDH inhibitor; IDH vaccine; glioma; isocitrate dehydrogenase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between IDH1/2 mutation and glioma.
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. . CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. (2017) 19:v1–88. 10.1093/neuonc/nox158 - DOI - PMC - PubMed
    1. Ohba S, Mukherjee J, See WL, Pieper RO. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res. (2014) 74:4836–44. 10.1158/0008-5472.CAN-14-0924 - DOI - PMC - PubMed
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. (2007) 114:97–109. 10.1007/s00401-007-0243-4 - DOI - PMC - PubMed
    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. . The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (2016) 131:803–20. 10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Wirsching HG, Weller M. The role of molecular diagnostics in the management of patients with gliomas. Curr Treat Options Oncol. (2016) 17:51. 10.1007/s11864-016-0430-4 - DOI - PubMed

LinkOut - more resources